Navigation Links
Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
Date:5/28/2008

dvanced bladder cancer,

metastatic adenocarcinoma of the prostate, hormone refractory prostate

cancer, and other areas of urological infections and malignancies. He

has authored or co-authored more than 450 articles published in

peer-reviewed journals and has published five textbooks and authored

more than 50 book chapters. He is an editorial reviewer or consultant

for many publications, including Urology, Journal of Urology, The New

England Journal of Medicine, Cancer and the Journal of Clinical

Oncology. Dr. Crawford is a member of the American Urological

Association (AUA), for which he was a member of the Prostate Cancer

Clinical Trials Subcommittee. He currently serves on the board of

governors, the GU committee, and the scientific advisory board of the

Southwest Oncology Group and chairs the National Prostate Cancer

Education Council. He received his medical degree from the University

of Cincinnati and completed an internship and residency in urology at

the Good Samaritan Hospital in Cincinnati. He completed a genitourinary

cancer fellowship at the University of California Medical Center in Los

Angeles.

-- Robert F. Ozols, M.D., Ph.D., is senior vice president of Fox Chase

Cancer Center in Philadelphia, where he oversees all of the Center's

patient care, clinical research and medical science laboratory

research. Internationally recognized for his expertise in ovarian

cancer, Dr. Ozols' research focuses on how cancer cells develop

resistance to anticancer drugs and on developing new chemotherapy

regimens for ovarian cancer. He previously served on the Oncologic

Drugs Advisory Committee (ODAC) of the Food and Drug Administration. He

is a former vice president of the International Gynecologic Cancer

Society and served on the Bo
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
2. Poniard Pharmaceuticals Announces Upcoming Conference Participation
3. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
4. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
6. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
7. XTL Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of Directors
8. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
9. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
10. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
11. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June ... of the Adult Stem Cell Technology Center, LLC ( ... under appreciated unique property of adult tissue stem cells. ... Misunderstood in the Past, Important for the Future,” embodied ... He gave the address at the 4th World Congress ...
(Date:12/24/2014)... 23, 2014 On Friday, December ... 83, the Omnibus and Continuing Resolution Appropriations Act ... hydrocephalus a condition eligible to receive funding through ... by the Department of Defense (DoD). The Hydrocephalus ... on Capitol Hill, is celebrating this victory for ...
(Date:12/24/2014)... Texas (PRWEB) December 23, 2014 ... methyl mercaptan such as its definition, classification, ... presents product specification, manufacturing process, and product ... technology and applications. The analysis also covers ... marketing channels, industry development trend and proposals. ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... (Nasdaq: NTII ) (NTI(R)) today announced that ... XERECEPT(R). , NTI ... to Celtic in,November 2005. NTI is entitled to receive ... if XERECEPT is approved for,commercial sale, NTI is also ...
... Treatment Determining Who Can Benefit from Vectibix(R) , ... Dec. 16 Amgen (Nasdaq: AMGN ) today ... KRAS gene as a predictive biomarker in ... growth factor receptor (EGFr) antibody Vectibix(R) (panitumumab) with the ...
... NJ, Dec. 16 /PRNewswire/ - DNP Green Technology and ... venture has obtained the necessary permits and begun construction ... acid. The succinic acid plant will have an annual ... integrated into an existing bio-refinery located in Pomacle, France. ...
Cached Biology Technology:Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 2Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 3Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 2Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 3Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 4Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 5Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 6Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 7Oncology Biomarker KRAS to be Discussed at FDA Panel Meeting 8Bioamber announces world's first bio-based succinic acid plant: helping to reduce dependence on fossil fuels 2Bioamber announces world's first bio-based succinic acid plant: helping to reduce dependence on fossil fuels 3
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
(Date:11/21/2014)... NEW YORK , Nov. 19, 2014  Earlier ... Board at New York College, and one of the ... for biosensor signals that are transmitted from Smartphones to ... there were Smartphones and has one of the earliest ... are discussing its usage in the military, child care, ...
(Date:11/18/2014)... WASHINGTON , Nov. 18, 2014  The ... Security Industry Association today jointly announce the formation ... and release of its Identity and Biometric ... (Framework). The Framework received official support from BORDERPOL, ... governments to improve and provide expertise regarding border ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... CACellulose is a fibrous molecule that makes up plant cell ... of renewable, plant-based biofuels research. But how it forms, and ... is not well understood. Now a study led by researchers ... that the underlying protein network that provides the scaffolding for ...
... uses chemical warfare to fight off competitors employs an ... researchers report, making use of an enzyme that can ... break a non-activated carbon-carbon bond in a single step. ... Nature , provides the first three-dimensional structure of ...
... There won,t be anymore waiting in the dark at this ... by a group of engineering researchers at McMaster University has ... The researchers are also hoping that the prototype ... The bus shelter is located on the west side of ...
Cached Biology News:Advance in understanding cellulose synthesis 2Advance in understanding cellulose synthesis 3Researchers describe 'implausible' chemistry that produces herbicidal compound 2Flexible solar strips light up campus bus shelter 2
... BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C 14 ... O 6 ,M.W.= 408.63 ,Assay: ... (2% in DMF) ,Biological Activity: Blue ... ,Elemental Analysis: Agrees with theoretical values ...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
Provides continuous mixing action. For use with tubes, vials, and other containers...
Agarose for baculovirus plaque assays which allow optimal growth of plated insect cells....
Biology Products: